介入治疗肝硬化门脉高压症并发食管胃底静脉曲张破裂出血研究进展*

doi:10.3969/j.issn.1672-5069.2016.05.003

Abstract

Shi Qing, Guo Wuhua.. Interventional treatment of variceal bleeding in cirrhotic patients[J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2016, 19(5): 519-523.

[1] Sarin SK,Kumar A,Angus PW,et al. Diagnosis and management of acute variceal bleeding:Asian Pacific Association for Study of the Liver recommendations. Hepatol Int,2011,5（2）:607-624.
[2] 中华医学会肝病学分会、消化病学分会、消化内镜学分会. 肝硬化门静脉高压食管胃静脉曲张出血的防治指南. 中华内科杂志,2016,55（1）:57-72.
[3] Hadduck TA,McWilliams JP. Partial splenic artery embolization in cirrhotic patients. World J Radiol,2014,6（5）:160-168.
[4] Alwmark A,Bengmark S,Gullstrand P,et al. Evaluation of splenic embolization in patients with portal hypertension and hypersplenism. Ann Surg,1982,196（5）:518-524.
[5] 刘学键,李恩山,马幼平,等. 联合介入栓塞治疗门静脉高压症的临床研究. 中国普通外科杂志,2008,18（1）:70-74.
[6] Gong WD,Xue K,Chu YK,et al. Percutaneous transhepatic embolization of gastroesophageal varices combined with partial splenic embolization for the treatment of variceal bleeding and hypersplenism. Int J Clin Exp Med,2015,8（10）:19642-19661.
[7] Ohmoto K,Yamamoto S. Prevention of variceal recurrence,bleeding,and death in cirrhosis patients with hypersplenism,especially those with severe thrombocytopenia. Hepatogastroenterology,2003,50（54）:1766-1769.
[8] Tian X,Shi Y,Hu J,et al. Percutaneous transhepatic variceal embolization with cyanoacrylate vs. transjugular intrahepatic portal systematic shunt for esophageal variceal bleeding. Hepatol Int,2013,7（2）:636-644.
[9] Duan X,Zhang K,Han X,et al. Comparison of percutaneous transhepatic variceal embolization（PTVE） followed by partial splenic embolization versus PTVE alone for the treatment of acute esophagogastric variceal massive hemorrhage. J Vasc Interv Radiol,2014,25（12）:1858-1865.
[10] 周光文,杨连粤. 肝硬化门静脉高压症食管、胃底静脉曲张破裂出血诊治专家共识（2015）. 中国实用外科杂志,2015,35（10）:1086-1090.
[11] Kapoor A,Dharel N,Sanyal AJ. Endoscopic diagnosis and therapy in gastroesophageal variceal bleeding. Gastrointest Endosc Clin N Am,2015,25（3）:491-507.
[12] Triantafyllou M,Stanley AJ. Update on gastric varices. World J Gastrointest Endosc,2014,6（5）:168-175.
[13] Kwak HS1,Han YM. Percutaneous transportal sclerotherapy with N-butyl-2-cyanoacrylate for gastric varices:technique and clinical efficacy. Korean J Radiol,2008,9（6）:526-533.
[14] Wang J,Tian XG,Li Y,et al. Comparison of modified percutaneous transhepatic variceal embolization and endoscopic cyanoacrylate injection for gastric variceal rebleeding. World J Gastroenterol,2013,19（5）:706-714.
[15] Kanagawa H,Mima S,Kouyama H,et al. Treatment of gastric fundal varices by balloon-occluded retrograde transvenous obliteration. J Gastroenterol Hepatol,1996,11（1）:51-58.
[16] Hashizume M,Tsugawa K,Migo S,et al. Eradication of large gastric varices by sclerotherapy combined with percutaneous transhepatic obliteration. Hepatogastroenterology,1997,44（13）:221-226.
[17] Violi F,Ferro D,Basili S,et al. Hyperfibrinolysis resulting from clotting activation in patients with different degrees of cirrhosis. Hepatology,1993,17（1）:78-83.
[18] Parikh S,Shah R,Kapoor P. Portal vein thrombosis. Am J Med,2010,123（2）:111-119.
[19] Molmenti EP,Roodhouse TW,Molmenti H,et al. Thrombendvenectomy for organized portal vein thrombosis at the time of liver transplantation. Ann Surg,2002,235（2）:292-296.
[20] Amitrano L,Guardascione MA,Brancaccio V,et al. Risk factors and clinical presentation of portal vein thrombosis in patients with liver cirrhosis. J Hepatol,2004,40:736-741.
[21] Chawla YK,Bodh V. Portal vein thrombosis. J Clin Exp Hepatol,2015,5（1）:22-40.
[22] 吴刚,刘永锋,陈旭春. 肝移植门静脉血栓形成的预防和治疗. 中华器官移植杂志,2006,27（10）:612-624.
[23] 高坌,王剑锋,魏宝杰,等.肝移植术后门静脉狭窄的血管内介入治疗. 中华器官移植杂志,2012,33（5）:291-294.
[24] Cheng YF,Ou HY,Tsang LL,et al. Vascular stents in the management of portal venous complications in living donor liver transplantation. Am J Transplant,2010,10（5）:1276-1283.
[25] Habib A,Desai K,Hickey R,et al. Portal vein recanalization- transjugular intrahepatic portosystemic shunt using the transsplenic approach to achieve transplant candidacy in patients with chronic portal vein thrombosis. J Vasc Interv Radiol,2015,26（4）:499-506.
[26] 韩国宏,孟祥杰,殷占新,等. 经颈内静脉肝内门腔分流术及联合经皮肝/脾穿刺途径治疗门静脉血栓和（或）海绵样变性. 中华医学杂志,2009,89（22）:1549-1552.
[27] Holster IL,Tjwa ET,Moelker A,et al. Covered transjugular intrahepatic portosystemic shunt versus endoscopic therapy+ β-blocker for prevention of variceal rebleeding. Hepatology,2016,63（2）:581-589.
[28] Lauermann J,Potthoff A,Mc Cavert M,et al. Comparison of technical and clinical outcome of transjugular portosystemic shunt placement between a bare metal stent and a PTFE-stentgraft device. Cardiovasc Intervent Radiol,2016,39（4）:547-556.
[29] Boyer TD,Haskal ZJ. The role of transjugular intrahepatic portosystemic shunt （TIPS） in the management of portal hypertension:update 2009. Hepatology,2010,51（1）:306.
[30] 中华医学会消化病学分会,中华医学会肝病学分会,中华医学会消化内镜学分会. 肝硬化门静脉高压食管胃静脉曲张出血的防治共识（2008,杭州）. 中华消化杂志,2008,28（8）:551-558.
[31] Grunwald D,Tapper EB,Jiang ZG,et al. A standardized assessment of functional disability predicts 1-year mortality in patients undergoing transjugular intrahepatic portosystemic shunt for refractory ascites. J Clin Gastroenterol,2016,50（1）:75-79.
[32] Mancuso A. An update on management of Budd-Chiari syndrome. Ann Hepatol,2014,13（3）:323-326.
[33] Raja K,Jacob M,Asthana S. Portal vein thrombosis in cirrhosis. J Clin Exp Hepatol,2014,4（4）:320-331.
[34] García-Pagán JC,Caca K,Bureau C,et al. Early use of TIPS in patients with cirrhosis and variceal bleeding. N Engl J Med,2010,362（25）:2370-2379.
[35] De Franchis R, Baveno V Faculty. Revising consensus in portal hypertension:report of the Baveno V consensus workshop on methodology of diagnosis and therapy in portal hypertension. J Hepatol,2010,53（4）:762-768.
[36] De Franchis R,Baveno VI Faculty. Expanding consensus in portal hypertension：Report of the Baveno VI Consensus Workshop：Stratifying risk and individualizing care for portal hypertension. J Hepatol,2015,63（3）:743-752.
[37] Tripathi D,Stanley AJ,Hayes PC,et al. Clinical Services and Standards Committee of the British Society of Gastroenterology.U.K. guidelines on the management of variceal haemorrhage in cirrhotic patients. Gut,2015,64（11）:1680-1704.
[38] Garcia-Pagán JC,Di Pascoli M,Caca K,et al. Use of early-TIPS for high-risk variceal bleeding:results of a post-RCT surveillance study. J Hepatol,2013,58（1）:45-50.
[39] Charon JP,Alaeddin FH,Pimpalwar SA,et al. Results of a retrospective multicenter trial of the Viatorr expanded polytetrafluoroethylene-covered stent-graft for transjugular intrahepatic portosystemic shunt creation. Vasc Interv Radiol,2004,15（11）:1219-1230.
[40] Hausegger KA,Karnel F,Georgieva B,et al. Transjugular intrahepatic portosystemic shunt creation with the Viatorr expanded polytetrafluoroethylene-covered stent-graft. J Vasc Interv Radiol, 2004,15（3）:239-248.
[41] Sauerbruch T,Mengel M,Dollinger M,et al. Prevention of rebleeding from esophageal varices in patients with cirrhosis receiving small-diameter stents versus hemodynamically controlled medical therapy. Gastroenterology,2015,149（3）:660-668.
[42] Habib A,Desai K,Hickey R,et al. Portal vein recanalization-transjugularintrahepatic portosystemic shunt using the transsplenic approach to achieve transplant candidacy in patients with chronic portal vein thrombosis. J Vasc Interv Radiol,2015,26（4）:499-506.
[43] Bissonnette J,Garcia-Pagán JC,Albillos A,et al. Role of the transjugular intrahepatic portosystemic shunt in the management of severe complications of portal hypertension in idiopathic noncirrhotic portal hypertension. Hepatology,2016,Mar 17. doi:10.1002/hep.28547. [Epub ahead of print]

Interventional treatment of variceal bleeding in cirrhotic patients

PDF (PC)

Knowledge

Abstract

Cite this article

share this article

References

Related Articles 15

Recommended Articles

Metrics

Comments

[1]	Zhuang Ying, Lin Zhihui.. Clinical manifestations and diagnosis of portal vein thrombosis [J]. Journal of Practical Hepatology, 2019, 22(6): 765-767.
[2]	Yang Caiyong, Chen Na, Li Kui, et al.. Clinical significance of peripheral blood Treg and Th17 cells in patients with chronic hepatitis C and hepatitis C-induced liver cirrhosis [J]. Journal of Practical Hepatology, 2019, 22(6): 868-871.
[3]	Zhu Yage, Liu Jinfeng.. Therapeutic efficacy of adenosine methionine and glycyrrhizin combination in treatment of patients with alcoholic cirrhosis and its effect on serum BGP levels [J]. Journal of Practical Hepatology, 2019, 22(6): 872-875.
[4]	Wu Dan Ma Xiangying.. Insulin resistance,carotid atherosclerosis and left ventricular function in patients with NAFLD-induced liver cirrhosis [J]. Journal of Practical Hepatology, 2019, 22(6): 876-879.
[5]	Chen Meimei, Duan Xiaoyan, Cao Haixia, et al.. Improvement of clinical symptoms and serum hepatic fibrosis markers in patients with primary biliary cirrhosis by compound Biejiaruangan tablets [J]. Journal of Practical Hepatology, 2019, 22(6): 880-883.
[6]	Liu Li, Yang Lie, Chen Haiyang, et al.. Changes of hemodynamics after splenectomy combined with pericardial devascularization in patients with cirrhotic portal hypertention complicated by splenic artery steal syndrome [J]. Journal of Practical Hepatology, 2019, 22(6): 884-887.
[7]	He Zhi’an, Yu Liping, Lai Jiangqiong, et al.. Evaluation of varices bleeding and portal vein thrombosis by ARFI in patients with cirrhosis and esophagogastric varices [J]. Journal of Practical Hepatology, 2019, 22(6): 888-891.
[8]	Du Keye, Yang Dongliang, Liu Jia. Regulatory T cells in hepatitis B [J]. Journal of Practical Hepatology, 2019, 22(5): 613-616.
[9]	Wang Yueyuan, Wang Yan, Zhang Dandan. Short-term efficacy of terlipressin and octreotide combination in treatment of cirrhotic patients complicated by hepatorenal syndrome [J]. Journal of Practical Hepatology, 2019, 22(5): 684-687.
[10]	Zhang Mei, Shi Xiuying, Li Linjuan, et al. Hepatic expression of interferon inducible protein -10 in patients with hepatitis B liver cirrhosis and hepatogenic diabetes mellitus [J]. Journal of Practical Hepatology, 2019, 22(5): 688-691.
[11]	Dan Zhuyongji, Liu Zhilan, Lu Yanyan, et al. Efficacy of endoscopic sequential variceal 1igation plus sclerotherapy in treatment of patients with hepatitis B-induced liver cirrhosis complicated by esophageal gastric varices bleeding [J]. Journal of Practical Hepatology, 2019, 22(5): 692-695.
[12]	Huang Hanjun, Lu Fengrong, Zhang Can. Clinical value of MRI scanning based on exchange hemodynamics model in evaluating liver cirrhosis [J]. Journal of Practical Hepatology, 2019, 22(5): 696-699.
[13]	Zhao Fangfang, Zhai Yongzhen, Feng Guohe. Efficacy and safety of autologous peripheral blood stem cell transplantation in patients with hepatitis B cirrhosis [J]. Journal of Practical Hepatology, 2019, 22(5): 700-703.
[14]	Chen Shan, Zhuang Huashuai, Xing Yixi, et al. Preventive application of meropenem in patients with liver cirrhosis complicated by upper gastrointestinal bleeding [J]. Journal of Practical Hepatology, 2019, 22(5): 704-707.
[15]	Xu Qilin, Hao Shaohuan, Ran Bo. Risk factors of portal vein thrombosis after splenectomy in patients with liver cirrhosis and portal hypertension [J]. Journal of Practical Hepatology, 2019, 22(5): 708-711.